Natural Product (NP) Details
| General Information of the NP (ID: NP0031) | |||||
|---|---|---|---|---|---|
| Name |
Hesperetin
|
||||
| Synonyms |
Hesperin; TNP00238; YSO2; Cyanidanon 4'-methyl ether 1626; Flavanone, 3',5,7-trihydroxy-4'-methoxy-(VAN); Flavanone, 3',5,7-trihydroxy-4'-methoxy-(VAN) (8CI); (-)-hesperetin; (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-2,3-dihydro-4H-chromen-4-one; (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-2,3-dihydrochromen-4-one; (S)-2,3-Dihydro-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4-benzopyrone; (S)-2,3-dihydro-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4H-1-benzopyran-4-one; 3',5,7-Trihydroxy-4'-methoxyflavanone; 3',5,7-Trihydroxy-4-methoxyflavanone; 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-, (S)-(9CI); 5,7,3'-Trihydroxy-4'-methoxyflavanone
Click to Show/Hide
|
||||
| Species Origin | Citrus limon ... | Click to Show/Hide | |||
| Citrus limon | |||||
| Citrus sinensis | |||||
| Citrus unshiu | |||||
| Disease | Hypertriglyceridaemia [ICD-11: 5C80] | Approved | [1] | ||
| Structure |
|
Click to Download Mol2D MOL |
|||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
| Formula |
C16H14O6
|
||||
| PubChem CID | |||||
| Canonical SMILES |
COC1=C(C=C(C=C1)C2CC(=O)C3=C(C=C(C=C3O2)O)O)O
|
||||
| InChI |
1S/C16H14O6/c1-21-13-3-2-8(4-10(13)18)14-7-12(20)16-11(19)5-9(17)6-15(16)22-14/h2-6,14,17-19H,7H2,1H3/t14-/m0/s1
|
||||
| InChIKey |
AIONOLUJZLIMTK-AWEZNQCLSA-N
|
||||
| CAS Number |
CAS 520-33-2
|
||||
| ChEBI ID | |||||
| Herb ID | |||||
| ETMC ID | |||||
| SymMap ID | |||||
| TCMSP ID | |||||
| TTD Drug ID | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
| Cisplatin | Bladder cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | AIFM1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP9 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CCND1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | PTEN | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | PTEN | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | GES-1 | CVCL_EQ22 | Healthy | Homo sapiens | ||
| HGC-27 | CVCL_1279 | Gastric carcinoma | Homo sapiens | |||
| SGC-7901 | CVCL_0520 | Human gastric cancer | Homo sapiens | |||
| MGC-803 | CVCL_5334 | Gastric mucinous adenocarcinoma | Homo sapiens | |||
| HGC-27/DDP | Gastric carcinoma | Homo sapiens | ||||
| In-vivo Model | HGC-27 cells were suspended in 100 ul of PBS, and then implanted into the dorsal area, subcutaneously, of male BALB/c nude mice. | |||||
| Experimental
Result(s) |
Hesperetin could inhibit the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/AKT signaling pathway and induce the mitochondrial pathway via upregulating PTEN expression, thereby significantly enhancing DDP's anti-tumor effect on GC. | |||||
| Platinum | Diabetes mellitus | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [3] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | UGT1A6 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
| LL/2 (LLC1) | CVCL_4358 | Malignant tumors | Mus musculus | |||
| In-vivo Model | Xenograft tumors were established by subcutaneous injection of 1*106 LLC cells into 6-week-old male C57BL/6 mice. | |||||
| Experimental
Result(s) |
Hesperetin can synergize platinum drugs by inhibiting UGT1A3 and increasing levels of reactive oxygen species (ROS). | |||||
| Doxorubicin | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [4] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | HER2 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | MMP-9 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | RNASE1 | Molecule Info | |||
| In-vitro Model | MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
The combination of Hst and Dox-induced cell cycle arrest, apoptosis, decreased HER2, Rac1, MMP9 expression, and cell migration. | |||||
| Etoposide | Testicular carcinoma | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [5] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Biological
Regulation |
Induction | Cell cycle arrest in G2 phase | ||||
| In-vitro Model | U2OS | CVCL_0042 | Osteosarcoma | Homo sapiens | ||
| Experimental
Result(s) |
Hesperetin combined with etoposide showed additive effects on the inhibition of cell growth. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Diacylglycerol acyltransferase 1 (DGAT1) | Molecule Info | [6] | |
| BioCyc | Triacylglycerol biosynthesis | Click to Show/Hide | ||
| KEGG Pathway | Glycerolipid metabolism | Click to Show/Hide | ||
| 2 | Retinol metabolism | |||
| 3 | Metabolic pathways | |||
| 4 | Fat digestion and absorption | |||
| Pathwhiz Pathway | Retinol Metabolism | Click to Show/Hide | ||
| Reactome | Acyl chain remodeling of DAG and TAG | Click to Show/Hide | ||
| 2 | Triglyceride Biosynthesis | |||
| WikiPathways | Vitamin A and Carotenoid Metabolism | Click to Show/Hide | ||
| 2 | Statin Pathway | |||
| 3 | Triacylglyceride Synthesis | |||
| 4 | Glycerophospholipid biosynthesis | |||
| 5 | Fatty acid, triacylglycerol, and ketone body metabolism | |||
